Beone Medicines

This study tests if a shot under the skin works as well as an IV drip for a cancer drug (tislelizumab) combined with chemotherapy in adults with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. About 351 participants will recei…

This early-stage study tests a new drug called BG-75202, alone or with other treatments, in people with advanced breast cancer or other solid tumors that have stopped responding to standard care. The main goals are to check safety, find the right dose, and see if the drug shrinks…

This study tests a new drug called sonrotoclax, alone or with other medicines, in people with a type of multiple myeloma that has come back or not responded to treatment. The goal is to see if the drug is safe and helps shrink the cancer. About 246 adults with a specific genetic …

This study tests a new drug, BGB-16673, against standard treatments (like idelalisib plus rituximab or bendamustine plus rituximab) in 250 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already been treated with both BTK and BCL2 inhib…

This study tests a new drug called BG-C0902 for people with advanced solid tumors that have not responded to other treatments. The drug is designed to attach to specific proteins on cancer cells and deliver a chemotherapy-like payload directly to them. The main goals are to check…

This early-stage study is testing a new drug called BG-A3004 for the first time in humans. It aims to check the drug's safety in healthy volunteers and in people with immune-related skin diseases. The study will give either one or four doses and follow participants for about 168 …

This early-phase study tests a new drug called BGB-43395, which blocks a protein (CDK4) that helps cancer cells grow. It is for people with advanced HR+/HER2- breast cancer or other solid tumors that have spread. The main goal is to find the safest and most effective dose, either…

This study tests a new drug called BGB-16673 in 150 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer came back or stopped responding to previous BTK inhibitor pills. Participants are randomly assigned to get BGB-16673 or one of two s…

This study tests a new drug, sonrotoclax, combined with antibody therapy for adults with relapsed or hard-to-treat chronic lymphocytic leukemia or small lymphocytic lymphoma. About 630 participants will be randomly assigned to receive either the new combination or a standard trea…

This early-phase study tests a new drug called BG-C477, alone or with other cancer treatments, in people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About …

This study tests a new drug, BGB-16673, against another drug, pirtobrutinib, in people whose chronic lymphocytic leukemia or small lymphocytic lymphoma has returned or stopped responding to prior treatment. About 500 participants will receive one of the two drugs to see which wor…

This study is testing whether a drug called tislelizumab, when combined with chemotherapy, can help control advanced stomach or esophageal cancer in US racial and ethnic minority patients. About 30 adults who have not had prior treatment for their cancer will receive the drug com…

This study is testing an experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors…

This study tests an experimental drug, BGB-16673, designed to destroy a protein that helps certain blood cancers grow. It is for people with B-cell cancers like lymphoma or leukemia that have come back or not responded to other treatments. The trial has two parts: first finding a…

This study compares a new drug pair (sonrotoclax plus zanubrutinib) to a standard pair (venetoclax plus acalabrutinib) in 500 adults with untreated chronic lymphocytic leukemia (CLL). The goal is to see which combination better delays disease progression and clears cancer cells f…

This study tests a new drug called BGB-16673, which breaks down a protein that helps cancer cells grow, combined with other treatments. It is for people with B-cell blood cancers (like lymphoma) that have returned or not responded to prior therapy. The goal is to find safe doses …

This early-phase study tests a new experimental drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The main goals are to check the drug's safety, find the best dose, and see if …

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Abo…

This study tests whether adding sonrotoclax to the standard drug zanubrutinib helps adults with mantle cell lymphoma that has returned or stopped responding to prior treatments. About 300 participants will receive either the combination or a placebo plus zanubrutinib. The main go…

This early-stage study tests a new drug (BGB-21447) combined with standard hormone therapy, with or without another targeted drug, in people with HR+/HER2- breast cancer that has spread. The goal is to find safe doses and see if the combination can shrink tumors. About 120 adults…

This early-phase study tests an experimental drug called BGB-26808, either alone or combined with an immunotherapy (tislelizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find the safest and most effective dose…

This early-phase study tests a new drug called BG-C137 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a cancer-killing agent directly to cells with a specific marker (FGFR2b). The main goals are to check safety…

This study tests a new drug called BG-C9074, which is designed to attach to a protein on cancer cells and deliver a toxic payload. The trial is for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the…

This early-stage study tests a new drug, BGB-B2033, alone or with other medicines, in people with advanced liver, stomach, lung, or yolk sac cancers that have spread. The main goals are to check safety and find the right dose. About 140 participants will take part.